Results
SMS Pharmaceuticals FY26 PAT Up 48% to ₹102 Crore
SMS Pharmaceuticals reported a 48% YoY rise in FY26 consolidated PAT to ₹102 crore, including share of profit from associate VKT Pharma.
FY26 EBITDA margin expanded 155 bps to 19%, driven by backward
